ALBO / Albireo: Successful And Accelerating Global Launch Drives Sales Revenue

Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year. more_horizontal

Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is po more_horizontal

Albireo promotes international sales of its approved product Bylvay for the treatment of the extremely rare and orphan disease PFIC. Investors do not more_horizontal

Albireo Pharma, Inc. (NASDAQ:ALBO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director-Li more_horizontal

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers ho more_horizontal

The lead medicine (Bylvay) is already approved to treat an orphan disease known as progressive familial intrahepatic cholestasis. Leveraging a prudent more_horizontal

Albireo Pharma (ALBO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Albireo Pharma (ALBO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal